Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588532 | 0.97 | ALDH1A1 (0.41) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL2583925 | 0.97 | ALDH1A1 (0.41) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL2588522 | 0.93 | ALDH1A1 (0.40) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL2589685 | 0.92 | ALDH1A1 (0.41) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL2583909 | 0.92 | ALDH1A1 (0.41) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL14737779 | 0.92 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL14737187 | 0.91 | ALDH1A1 (0.41) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL2590692 | 0.89 | ALDH1A1 (0.44) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL2589004 | 0.89 | ALDH1A1 (0.44) | ALDH1A1GAAKDM4EHPGDS1PR1 | |
| SCHEMBL14737178 | 0.88 | ALDH1A1 (0.37) | ALDH1A1GAAKDM4EHPGDS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | ALDH1A1 824/4885GAA 202/4885KDM4E 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.